Mutant Sodium Channel for Tumor Therapy

AUTOR(ES)

Tannous, Bakhos A

FONTE

Nature Publishing Group

RESUMO

Viral vectors have been used to deliver a wide range of therapeutic genes to tumors. In this study, a novel tumor therapy was achieved by the delivery of a mammalian brain sodium channel, ASIC2a, carrying a mutation that renders it constitutively open. This channel was delivered to tumor cells using a herpes simplex virus-1/Epstein–Barr virus (HSV/EBV) hybrid amplicon vector in which gene expression was controlled by a tetracycline regulatory system (tet-on) with silencer elements. Upon infection and doxycycline induction of mutant channel expression in tumor cells, the open channel led to amiloride-sensitive sodium influx as assessed by patch clamp recording and sodium imaging in culture. Within hours, tumor cells swelled and died. In addition to cells expressing the mutant channel, adjacent, noninfected cells connected by gap junctions also died. Intratumoral injection of HSV/EBV amplicon vector encoding the mutant sodium channel and systemic administration of doxycycline led to regression of subcutaneous tumors in nude mice as assessed by in vivo bioluminescence imaging. The advantage of this direct mode of tumor therapy is that all types of tumor cells become susceptible and death is rapid with no time for the tumor cells to become resistant.

Documentos Relacionados

• Defective fast inactivation recovery and deactivation account for sodium channel myotonia in the I1160V mutant.
• Two sodium-channel genes in Drosophila: implications for channel diversity.
• Evidence That the Drosophila Olfactory Mutant Smellblind Defines a Novel Class of Sodium Channel Mutation
• Sodium-dependent regulation of epithelial sodium channel densities in frog skin; a role for the cytoskeleton.
• Ozone Therapy for Tumor Oxygenation: a Pilot Study